# Durvalumab (MEDI4736) and Radiosurgery (fSRT Vs. PULSAR) for the Treatment of Non-Small Cell Lung Cancer Brain Metastases

> **NCT04889066** · PHASE2 · WITHDRAWN · sponsor: **University of Texas Southwestern Medical Center**

## Conditions studied

- Brain Metastases from Non-small Cell Lung Cancer

## Interventions

- **RADIATION:** Stereotactic Radiation Therapy
- **DRUG:** Durvalumab

## Key facts

- **NCT ID:** NCT04889066
- **Lead sponsor:** University of Texas Southwestern Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2024-10-01
- **Primary completion:** 2025-01
- **Final completion:** 2025-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Project Never Initiated since sponsor stopped support for the trial- no human subjects were enrolled and no data regarding humans was collected or studied
- **Last updated:** 2024-12-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04889066

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04889066, "Durvalumab (MEDI4736) and Radiosurgery (fSRT Vs. PULSAR) for the Treatment of Non-Small Cell Lung Cancer Brain Metastases". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04889066. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*